PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21209362-3	2011	Moreover, accumulating evidence suggests that eicosanoids derived from cyclooxygenase (COX)-2 participate in a number of pathological processes in immune-mediated renal diseases, and it is known that protein kinase B (AKT) may act through different transcription factors in the regulation of the COX-2 promoter.	Eicosanoids	46-57	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	71-93	
23682075-1	2013	COX-2 and 5-lipoxygenase (5-LO) use arachidonic acid for the synthesis of eicosanoids that have been implicated in carcinogenesis and cardiovascular disease.	Eicosanoids	74-85	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5	
23398566-7	2013	Following co-incubation with n-butyrate and lipopolysaccharide, key enzymes of the eicosanoid pathway, like PTGS2 (COX-2), TXS, ALOX5, LTA4H and LTC4S, were significantly up-regulated compared with stimulation with lipopolysaccharide alone.	Eicosanoids	83-93	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	115-120	
21916491-11	2011	These results show that 11-oxo-ETE is a novel COX-2/15-PGDH-derived eicosanoid, which inhibits endothelial cell proliferation with a potency that is similar to that observed for 15d-PGJ(2).	Eicosanoids	68-78	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	46-51	
28818745-6	2018	CONCLUSIONS: Extended research is necessary for the development of these novel compounds targeting the eicosanoid pathway, by increasing the levels of anti-inflammatory eicosanoids (PGD2,15dPGJ2), by inhibiting the production of pro-inflammatory eicosanoids (PGE2, LTB4, PGI2) involved in rheumatoid arthritis or also by developing dual compounds displaying both the COX-2 inhibitor/TP antagonist activity within a single compound.	Eicosanoids	103-113	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	367-372	
26677076-2	2016	Polyunsaturated fatty acids (PUFA) metabolism impaired by cyclooxygenases (COX-1, COX-2), which are responsible for formation of several eicosanoids, and by lipoxygenases (LOXs) that catalyze the addition of oxygen to linolenic, arachidonic (AA), and docosahexaenoic acids (DHA) and other PUFA leading to formation of bioactive lipids, significantly affects the course of neurodegenerative diseases.	Eicosanoids	137-148	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	82-87	
25369453-11	2014	Thus addition of AA to the culture media is skewing the DCs towards the secretion of more IL-12 and less of IL-10 along with the restoration of eicosanoids levels in a COX-2 mediated pathway thereby enhancing the functionality of these cells to be used as a potent cellular vaccine.	Eicosanoids	144-155	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	168-173	
24976682-6	2014	Red wine as a complex mixture is a powerful inhibitor of COX-1, COX-2, and 5-LOX, the enzymes involved in eicosanoid biosynthetic pathway.	Eicosanoids	106-116	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	64-69	
23945567-10	2013	Therefore, this study has established that the COX-2/15-PGDH-derived eicosanoids 11-oxo- and 15-oxo-ETE enter target cells, that they inhibit cellular proliferation, and that their inhibitory effects are modulated by MRP exporters.	Eicosanoids	69-80	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	47-52	
23398566-10	2013	Our results suggest that among many other mediators of eicosanoid signalling n-butyrate massively induces PGE(2) production by increasing the expression of PTGS2 (COX-2) in monocytes following TLR4 and TLR2 activation and induces secretion of LTB(4) and thromboxane B(2).	Eicosanoids	55-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	163-168	
22891999-2	2012	In these studies, we have (a) identified the diverse eicosanoid pathways that are activated in human chondrocytes of normal and OA cartilage, (b) delineated the modulation of eicosanoids in the presence of NSAIDS and selective COX-2 inhibitors, and (c) characterized eicosanoid products and various transcripts modulated by various inhibitors of eicosanoids in human OA cartilage by gene expression arrays.	Eicosanoids	175-186	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	227-232	
22891999-2	2012	In these studies, we have (a) identified the diverse eicosanoid pathways that are activated in human chondrocytes of normal and OA cartilage, (b) delineated the modulation of eicosanoids in the presence of NSAIDS and selective COX-2 inhibitors, and (c) characterized eicosanoid products and various transcripts modulated by various inhibitors of eicosanoids in human OA cartilage by gene expression arrays.	Eicosanoids	175-185	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	227-232	
21916491-2	2011	Stable isotope dilution chiral liquid chromatography (LC)-electron capture atmospheric pressure chemical ionization (ECAPCI)/mass spectrometry (MS) was used to quantify COX-2-derived eicosanoids in the human colorectal adenocarcinoma (LoVo) epithelial cell line, which expresses both COX-2 and 15-hydroxyprostaglandin dehydrogenase (15-PGDH).	Eicosanoids	183-194	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	169-174	
21209362-3	2011	Moreover, accumulating evidence suggests that eicosanoids derived from cyclooxygenase (COX)-2 participate in a number of pathological processes in immune-mediated renal diseases, and it is known that protein kinase B (AKT) may act through different transcription factors in the regulation of the COX-2 promoter.	Eicosanoids	46-57	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	296-301	
20840853-5	2010	Concentration- and time-dependent increases in mRNA and protein expression of eicosanoid biosynthetic enzymes including COX-2, 5-lipoxygenase, microsomal PGE2 synthases, leukotriene (LT) A4 hydrolase and LTC4 synthase were observed in CEES-treated skin equivalents, as well as in antioxidant enzymes, glutathione S-transferases A1-2 (GSTA1-2), GSTA3 and GSTA4.	Eicosanoids	78-88	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	120-125	
20593240-3	2010	Although this selective COX-2 inhibitor, like diet, may alter the fatty acid and eicosanoid pattern, data on the potential alteration in tissues after use, are scarce.	Eicosanoids	81-91	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29	
20477063-0	2009	Eicosanoids in inflammation and cancer: the role of COX-2.	Eicosanoids	0-11	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	52-57	
20117851-4	2010	This suggested that selective inhibition of the synthesis of COX-2-derived prostanoids could lead to undesired disruption of the intricate inter-eicosanoid network.	Eicosanoids	145-155	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	61-66	
17996418-3	2008	The arachidonic acid shunting hypothesis proposes that COX2 inhibitors" neuroprotective effects may be mediated by increased formation of potentially beneficial eicosanoids.	Eicosanoids	161-172	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	55-59	
18812633-5	2008	Selective NSAIDs were specifically designed to preferentially inhibit the cyclooxygenase-2 (COX-2), an inducible enzyme mediating the production of inflammatory eicosanoids in the joints but sparing the endogenous protective eicosanoids in the stomach.	Eicosanoids	161-172	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	92-97	
18812633-5	2008	Selective NSAIDs were specifically designed to preferentially inhibit the cyclooxygenase-2 (COX-2), an inducible enzyme mediating the production of inflammatory eicosanoids in the joints but sparing the endogenous protective eicosanoids in the stomach.	Eicosanoids	225-236	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	92-97	
19074288-1	2008	Cyclooxygenase (COX-1/COX-2)-catalyzed eicosanoid formation plays a key role in inflammation-associated diseases.	Eicosanoids	39-49	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27	
17996418-4	2008	Under conditions where COX2 activity is inhibited, arachidonic acid accumulates or is converted to eicosanoids via lipoxygenases and cytochrome P450 (CYP) epoxygenases.	Eicosanoids	99-110	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	23-27	
17305573-7	2007	In 1991, it was discovered that COX exists in two distinct isozymes, COX-1 and COX-2, of which COX-2 is primarily expressed at sites of inflammation and produces pro-inflammatory eicosanoids.	Eicosanoids	179-190	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	79-84	
17541796-5	2007	This clinical outcome was supported by the existence of plausible eicosanoid-based biological mechanisms whereby selective COX-2 inhibition could increase CV risk.	Eicosanoids	66-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	123-128	
17305573-7	2007	In 1991, it was discovered that COX exists in two distinct isozymes, COX-1 and COX-2, of which COX-2 is primarily expressed at sites of inflammation and produces pro-inflammatory eicosanoids.	Eicosanoids	179-190	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100	
17961045-9	2007	CONCLUSIONS: Eicosanoid derivatives COX-1, COX-2, 5-LO, and PTGER4 enzymes show a high universal expression in meningiomas but are not upregulated in normal human cortex and dura tissue.	Eicosanoids	13-23	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48	
17927497-5	2007	Preferentially, Cox-2 inhibition can create a favorable pattern of cytokines by decreasing the production of certain eicosanoids, although their role in SIMS is unknown.	Eicosanoids	117-128	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	16-21	
16998585-1	2006	Tight regulation of COX-2 expression is a key feature controlling eicosanoid production in atherosclerosis and other inflammatory syndromes.	Eicosanoids	66-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	20-25	
16154102-3	2005	While this abnormal pattern of eicosanoid generation has been implicated in the development of vascular disease associated with COX-2 inhibition, its role in the development of hypertension, the most common cardiovascular complication associated with COX-2 inhibition, is not known.	Eicosanoids	31-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	128-133	
16760523-1	2006	Tissue expression of cyclooxygenase (COX)2, an inducible enzyme synthesizing eicosanoids in inflammation, was studied in reversal reaction (RR) leprosy in comparison with nonreactionary leprosy.	Eicosanoids	77-88	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	37-42	
16213697-4	2005	In this study, using reference COX-2, 5-LOX and dual COX-2/5-LOX inhibitors, we devised a protocol which permitted the simultaneous quantification of eicosanoid metabolites formed during stimulation of human peripheral venous blood samples with the calcium ionophore, A23187, in the absence and presence of lipopolysaccharide (LPS).	Eicosanoids	150-160	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	53-58	
15878913-6	2005	The upregulation of cox-2 and cPLA2 was inhibited by flurbiprofen, a cyclooxygenase (COX) inhibitor, making this a second feed-forward enzyme in the eicosanoid pathway.	Eicosanoids	149-159	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	20-25	
15618359-3	2005	Cyclooxygenase (COX)-2 and prostaglandin (PG)E(2), a major eicosanoid product of the COX-2-catalyzed pathway, play key roles in normal bone tissue remodeling.	Eicosanoids	59-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-22	
15990700-2	2005	In contrast, aspirin blocks both COX-1 and COX-2 enzymes that, in turn, increases intracellular concentrations of dihomo-gamma-linolenic acid (DGLA), arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and reduced formation of eicosanoids.	Eicosanoids	257-268	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48	
15887126-4	2005	Prostaglandins and other eicosanoids derived from COX-1 and COX-2 are involved in a variety of physiologic and pathologic processes in the gastrointestinal tract.	Eicosanoids	25-36	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	60-65	
15618359-3	2005	Cyclooxygenase (COX)-2 and prostaglandin (PG)E(2), a major eicosanoid product of the COX-2-catalyzed pathway, play key roles in normal bone tissue remodeling.	Eicosanoids	59-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	85-90	
15720401-9	2005	These studies suggest that cPLA2-alpha and COX-2 may function together at a distinct and novel compartment for eicosanoid signalling.	Eicosanoids	111-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	43-48	
15926604-4	2005	COX-2 inhibitors may decrease vascular prostacyclin production and may tip the balance in favour of prothrombotic eicosanoids (thromboxane A2) and lead to increased cardiovascular thrombotic events.	Eicosanoids	114-125	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5	
15254428-14	2004	Our findings provide new informations about individual eicosanoids produced by HNSCC cells and their differential regulation by the selective COX-2 inhibitor celecoxib.	Eicosanoids	55-66	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	142-147	
15555528-27	2005	COX-2 drives conversion of AA to a number angiogenic and proinflammatory eicosanoids.	Eicosanoids	73-84	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5	
15550400-3	2005	Cyclooxygenase (COX)-2, an inducible enzyme that catalyzes the conversion of arachidonic acid to prostaglandins and other eicosanoids, is also induced by hypoxia.	Eicosanoids	122-133	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-22	
12060588-9	2002	Acute NOS inhibition unmasked renal vasoconstriction with COX-2 inhibition, suggesting that the influence of COX-2-derived vasodilator eicosanoids is exaggerated to maintain renal perfusion, compensating for the acute loss of NO.	Eicosanoids	135-146	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	58-63	
15229941-1	2004	OBJECTIVE: Cyclooxygenase (COX)-2 is an inducible eicosanoid-forming enzyme that is expressed at sites of inflammation.	Eicosanoids	50-60	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	11-33	
15301300-2	2004	INTRODUCTION: Cyclooxygenases 1 (Cox-1) and 2 (Cox-2) play a key role in arachidonic acid metabolism and in the regulation of eicosanoid production.	Eicosanoids	126-136	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	47-52	
15301300-13	2004	The significance of these findings has to be discussed with regard to the regulatory function of Cox-2 in eicosanoid release and the role of the latter in the immunology and pathophysiology of nasal polyps.	Eicosanoids	106-116	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	97-102	
14762100-2	2004	Acetylation of COX-2 by aspirin activates a transcellular biosynthetic pathway that switches eicosanoid biosynthesis from prostaglandin E(2) to 15-epi-lipoxin (LX)A(4) or aspirin-triggered lipoxin (ATL).	Eicosanoids	93-103	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	15-20	
14693827-1	2004	Eicosanoids constitute a large family of biologically active lipid mediators that are produced by two enzyme classes, cyclooxygenases (COX-1 and COX-2) and lipoxygenases (5-LO, 12-LO, and 15-LO).	Eicosanoids	0-11	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	145-150	
12648159-3	2003	Physiological regulation of COX-2 in these cellular compartments suggests functional roles for eicosanoid products of the enzyme.	Eicosanoids	95-105	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	28-33	
12795055-3	2003	COX-2 appears to: (a) play a key role in the release and activity of proangiogenic proteins; (b) result in the production of eicosanoid products TXA2, PGI2, PGE2 that directly stimulate endothelial cell migration and angiogenesis in vivo, and (c) result in enhanced tumor cell, and possibly, vascular endothelial cell survival by upregulation of the antiapoptotic proteins Bcl-2 and/or activation of PI3K-Akt.	Eicosanoids	125-135	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5	
12060588-9	2002	Acute NOS inhibition unmasked renal vasoconstriction with COX-2 inhibition, suggesting that the influence of COX-2-derived vasodilator eicosanoids is exaggerated to maintain renal perfusion, compensating for the acute loss of NO.	Eicosanoids	135-146	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	109-114	
11173047-1	2001	Cyclooxygenase (COX)-1 and COX-2 catalyze the formation of prothrombotic and antithrombotic eicosanoids, respectively.	Eicosanoids	92-103	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	27-32	
12086293-6	2002	The COX-2-selective inhibitors, however, have also been shown to inhibit the production of vascular prostacyclin, which has vasodilatory effects and inhibits platelet aggregation; unlike nonselective NSAIDs, they do not inhibit the production of thromboxane, an eicosanoid that promotes platelet aggregation.	Eicosanoids	262-272	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	4-9	
11695251-1	2001	The isozymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) catalyze the conversion of arachidonic acid to eicosanoids that play an important role in the maintenance of cardiovascular hemostasis.	Eicosanoids	114-125	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	60-65	
11409487-0	2001	Eicosanoid production by human monocytes: does COX-2 contribute to a self-limiting inflammatory response?	Eicosanoids	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	47-52	
11287611-12	2001	The identification of distinct pathways through which eicosanoids regulate anti-inflammatory and antiproliferative effects may improve the utility of COX2 inhibitors.	Eicosanoids	54-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	150-154	
11552047-3	2001	These enzymes (Cox-1 and Cox-2) catalyze the synthesis of eicosanoids, which play an important part in platelet-vessel wall interactions.	Eicosanoids	58-69	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	25-30	
11478355-4	2001	Futhermore, selective COX-2 inhibitors may have other consequences as a result of the change in the eicosanoid profile.	Eicosanoids	100-110	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	22-27	
10953335-1	2000	Cyclooxygenase (COX), also referred to as prostaglandin endoperoxide synthase, is a key enzyme in the conversion of arachidonic acid to prostaglandins and other eicosanoids.	Eicosanoids	161-172	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	16-19	
10903770-9	2000	Furthermore, the inhibition of eicosanoid production by the action of nonsteroidal anti-inflammatory drugs or by the prevention of COX-2 induction with the p38 mitogen-activated protein kinase inhibitor SKF86002 was greater for PGE2 than for TXA2.	Eicosanoids	31-41	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	131-136	
10953335-10	2000	Furthermore, indomethacin and NS398 were equipotent for growth inhibition and induction of apoptosis, indicating that eicosanoid synthesis via COX-2 is involved in pancreatic cancer cell proliferation and survival.	Eicosanoids	118-128	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	143-148	
9276732-6	1997	This alteration in eicosanoid metabolism was associated with induction of cyclooxygenase (Cox)-2 and thromboxane synthase, but not Cox-1.	Eicosanoids	19-29	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	74-96	
10797288-1	2000	Cyclooxygenase (COX)-2 is one of the rate-limiting enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids.	Eicosanoids	125-136	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-22	
10811000-5	2000	Exposure to GBS caused monocytes to express COX-2 mRNA and protein in both a time- and concentration-dependent manner that correlated with eicosanoid production.	Eicosanoids	139-149	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	44-49	
10811000-8	2000	Our experiments are the first to show that exposure of monocytes to a gram-positive bacterium (GBS) results in induction of functional COX-2, suggesting that eicosanoids may play important roles in the pathogenesis of GBS infections.	Eicosanoids	158-169	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	135-140	
10877525-4	2000	However, such drugs may also trigger unwanted effects; for example, the COX-2 inhibitors, which reduce the production of one type of eicosanoids, the prostaglandins, may increase the production of other eicosanoids; i.e., the leukotriene B4 (LTB4), which is one of the most potent endogenous chemotactic/inflammatory factors.	Eicosanoids	133-144	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	72-77	
10877525-4	2000	However, such drugs may also trigger unwanted effects; for example, the COX-2 inhibitors, which reduce the production of one type of eicosanoids, the prostaglandins, may increase the production of other eicosanoids; i.e., the leukotriene B4 (LTB4), which is one of the most potent endogenous chemotactic/inflammatory factors.	Eicosanoids	203-214	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	72-77	
10514410-1	1999	Cyclooxygenase-1 (Cox-1) and Cox-2 convert arachidonic acid to prostaglandin H(2), the precursor of other prostaglandins and thromboxanes, eicosanoids important in vascular pathophysiology.	Eicosanoids	139-150	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	29-34	
9736253-2	1998	These findings suggest an integral role for eicosanoids generated by macula densa-associated COX-2 in mediating renin release.	Eicosanoids	44-55	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	93-98	
10744623-1	2000	The cyclooxygenases (COX)-1 and COX-2 are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids.	Eicosanoids	120-131	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	32-37	
10217524-23	1999	Cytokine-induced, COX-2-dependent eicosanoid production inhibits DNA synthesis.	Eicosanoids	34-44	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	18-23	
9766645-1	1998	Cyclooxygenase (COX)-2, an inducible enzyme that catalyzes the formation of prostaglandins and other eicosanoids from arachidonic acid, is constitutively expressed in LNCaP human prostate cancer cell line.	Eicosanoids	101-112	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-22	
9443418-3	1998	To explore the biochemical mechanisms involved in these effects, we have evaluated the role of COX-2-derived eicosanoid products on programmed cell death in human colon cancer cells.	Eicosanoids	109-119	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100	
9475035-14	1997	Older nonsteroidal antiinflammatory drugs like aspirin and indomethacin are non selective inhibitors of COX activity and therefore, in addition to inhibiting COX-2 activity, inhibit the formation of eicosanoids by COX-1.	Eicosanoids	199-210	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	158-163	
9276732-7	1997	Unlike results seen in other systems, the upregulation of Cox-2 and the subsequent release of eicosanoids by endothelial cells was not directly induced by complement but rather required production of IL-1alpha, which acted on endothelial cells as an autocrine factor.	Eicosanoids	94-105	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	58-63	
33038834-3	2020	SARS-CoV (2003) induces Cox-2, catalyzing the synthesis, from highly unsaturated fatty acids (HUFA), of eicosanoids and docosanoids that mediate both inflammation and thrombosis.	Eicosanoids	104-115	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	24-29	
9279772-3	1997	While COX-1 is thought to account for homeostatic amounts of eicosanoids, COX-2 is induced during inflammation leading to pathologic amounts of eicosanoids.	Eicosanoids	144-155	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	74-79	
9597082-3	1997	Recent data indicate that eicosanoids, primarily the products of the inducible form of cyclooxygenase (COX-2), are involved in the regulation of cytokine production.	Eicosanoids	26-37	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	103-108	
8257696-15	1993	Taken together, these data demonstrate that reduced eicosanoid synthesis in smooth muscle-derived foam cells is due, in part, to impaired transcription of mRNA for COX-1 and COX-2 as well as fatty acid remodeling in membrane phospholipids.	Eicosanoids	52-62	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	174-179	
33441691-9	2021	Further, COX-2 expression and LD amount presented a significant positive correlation and were detected co-localized in EAC, but not in ESCC, suggesting that LD may be the site for eicosanoid production in EAC.	Eicosanoids	180-190	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	9-14	
33016027-1	2020	SARS-Cov-2 infection causes local and systemic inflammation mediated by pro-inflammatory cytokines and COX-2 eicosanoid products with metabolic dysfunction and tissue damage that can lead to patient death.	Eicosanoids	109-119	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	103-108	
32505122-5	2020	COX-1 and COX-2 metabolize AA to bioactive eicosanoids.	Eicosanoids	43-54	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	10-15	
30168128-2	2019	Among the various eicosanoid metabolic pathways, studies of their role in endometrial cancer (EC) have very much been confined to the COX-2 pathway.	Eicosanoids	18-28	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	134-139	
31811862-5	2020	This study investigates the regulatory mechanisms exerted by other groups of bioactive eicosanoids derived from 12-lipoxygenase (12-LO), in particular 12-hydroxyeicosatetraenoic (12-HETE), on group IIA sPLA2-induced (i) PGE2 release, (ii) COX-2 expression, and (iii) activation of signaling pathways p38 mitogen-activated protein kinases p38 mitogen-activated protein kinases (p38MAPK), protein C kinase (PKC), extracellular signal-regulated kinase 1/2 (ERK1/2), and NF-kappaB.	Eicosanoids	87-98	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	239-244	
31480263-5	2019	Moreover, cyclooxygenase-1 (COX-1) activity was enhanced only in Ps, but cyclooxygenase-2 (COX-2) was enhanced both in Ps and PsA, generating higher levels of eicosanoids: prostaglandin E1 (PGE1), leukotriene B4 (LTB4), 13-hydroxyoctadecadienoic acid (13HODE), thromboxane B2 (TXB2).	Eicosanoids	159-170	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	91-96	
30429830-4	2018	In this study, gene expression analyses indicated that genes involved in eicosanoid biosynthesis including COX-1, COX-2, DAGL, and PLA-2 are differentially regulated in THP-1 human macrophages infected with Salmonella enterica Typhimurium or Yersinia enterocolitica.	Eicosanoids	73-83	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	114-119